Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irinotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Irinotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Carcinoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irinotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

    NCT05086822 · start 2014-09-09

    Registered record
    Registry ID
    NCT05086822
    Conditions
    Advanced Solid Tumors
    Interventions
    Irinotecan liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09-09
    Completion
    2017-08-28
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionIrinotecan liposome
    PhasePhase 1
    Registry statusCompleted

  • ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

    NCT02044120 · start 2014-05

    Registered record
    Registry ID
    NCT02044120
    Conditions
    Ewing Sarcoma
    Interventions
    niraparib; Temozolomide; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2021-01
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing Sarcoma
    Interventionniraparib; Temozolomide; Irinotecan
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

    NCT02004262 · start 2014-02-05

    Registered record
    Registry ID
    NCT02004262
    Conditions
    2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    Interventions
    GVAX Pancreas Vaccine; CRS-207; Chemotherapy; cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-02-05
    Completion
    2016-08-23
    Enrolment
    303

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
    InterventionGVAX Pancreas Vaccine; CRS-207; Chemotherapy; cyclophosphamide
    PhasePhase 2
    Registry statusCompleted

  • CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

    NCT01835041 · start 2013-04

    Registered record
    Registry ID
    NCT01835041
    Conditions
    Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
    Interventions
    6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride; fluorouracil; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-04
    Completion
    2023-03-16
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
    Intervention6,8-bis(benzylthio)octanoic acid; oxaliplatin; leucovorin calcium; irinotecan hydrochloride +2 more
    PhasePhase 1
    Registry statusCompleted

  • Metformin in Children With Relapsed or Refractory Solid Tumors

    NCT01528046 · start 2012-09-24

    Registered record
    Registry ID
    NCT01528046
    Conditions
    Solid Tumors; Primary Brain Tumors
    Interventions
    Vincristine; Irinotecan; Temozolomide; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-09-24
    Completion
    2020-02-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Primary Brain Tumors
    InterventionVincristine; Irinotecan; Temozolomide; Metformin
    PhasePhase 1
    Registry statusCompleted

  • Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

    NCT01441349 · start 2011-08

    Registered record
    Registry ID
    NCT01441349
    Conditions
    Small Cell Lung Carcinoma
    Interventions
    IP chemotherapy; IP chemotherapy plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-08
    Completion
    2022-12-31
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Carcinoma
    InterventionIP chemotherapy; IP chemotherapy plus simvastatin
    PhasePhase 2
    Registry statusUnknown

  • Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

    NCT01313884 · start 2011-05

    Registered record
    Registry ID
    NCT01313884
    Conditions
    Bone Cancer; Ewing's Sarcoma
    Interventions
    Irinotecan; Vincristine; Temozolomide; Doxorubicin; Cytoxan; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2014-07
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Cancer; Ewing's Sarcoma
    InterventionIrinotecan; Vincristine; Temozolomide; Doxorubicin +2 more
    PhasePhase 2
    Registry statusTerminated

  • Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

    NCT01375816 · start 2011-05

    Registered record
    Registry ID
    NCT01375816
    Conditions
    Colorectal Cancer
    Interventions
    FOLFIRI 1-Bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium; liposome-encapsulated irinotecan hydrochloride PEP02; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2014-12
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionFOLFIRI 1-Bevacizumab; fluorouracil; irinotecan hydrochloride; leucovorin calcium +2 more
    PhasePhase 2
    Registry statusTerminated

  • Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

    NCT01296763 · start 2011-01

    Registered record
    Registry ID
    NCT01296763
    Conditions
    Pancreatic Cancer
    Interventions
    Irinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2); Mitomycin-C
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-01
    Completion
    2016-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionIrinotecan; Cisplatin; Olaparib (for levels 1 and 5); Olaparib (for dose level 2) +1 more
    PhasePhase 1
    Registry statusCompleted

  • Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

    NCT00925015 · start 2009-06-17

    Registered record
    Registry ID
    NCT00925015
    Conditions
    Colorectal Cancer
    Interventions
    Dalotuzumab 10 mg/kg; Cetuximab; Irinotecan; Dalotuzumab 15/7.5 mg/kg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-06-17
    Completion
    2010-12-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionDalotuzumab 10 mg/kg; Cetuximab; Irinotecan; Dalotuzumab 15/7.5 mg/kg
    PhasePhase 1
    Registry statusCompleted

  • Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

    NCT01380275 · start 2008-04

    Registered record
    Registry ID
    NCT01380275
    Conditions
    Sarcoma
    Interventions
    Docetaxel (Taxotere); Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2008-04
    Completion
    2014-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionDocetaxel (Taxotere); Irinotecan
    PhasePhase 2
    Registry statusUnknown

  • AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

    NCT00535353 · start 2008-01-02

    Registered record
    Registry ID
    NCT00535353
    Conditions
    Colorectal Cancer
    Interventions
    irinotecan hydrochloride; olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-01-02
    Completion
    2015-02-13
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionirinotecan hydrochloride; olaparib
    PhasePhase 1
    Registry statusCompleted

  • Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

    NCT00492999 · start 2007-05

    Registered record
    Registry ID
    NCT00492999
    Conditions
    Colorectal Cancer; Metastatic Cancer
    Interventions
    dexamethasone; floxuridine; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2007-05
    Completion
    2027-05
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Metastatic Cancer
    Interventiondexamethasone; floxuridine; fluorouracil; irinotecan hydrochloride +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    NCT00057837 · start 2004-07-14

    Registered record
    Registry ID
    NCT00057837
    Conditions
    Extensive Stage Small Cell Lung Cancer
    Interventions
    G-CSF; Cisplatin; Etoposide; Irinotecan; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-07-14
    Completion
    2012-08
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive Stage Small Cell Lung Cancer
    InterventionG-CSF; Cisplatin; Etoposide; Irinotecan +1 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

    NCT00416767 · start 2004-05

    Registered record
    Registry ID
    NCT00416767
    Conditions
    Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
    Interventions
    fluorouracil; irinotecan hydrochloride; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2007-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
    Interventionfluorouracil; irinotecan hydrochloride; leucovorin calcium
    PhasePhase 2
    Registry statusCompleted